title: [Evaluation of the treatment effectiveness of domestic G-SCF preparations in experiments on irradiated dogs].
abstract: We have evaluated the treatment effectiveness of Leucostim and Neupomax in dogs exposed to radiation at lethal doses of 3 and 3.5 Gy, correspondingly, by testing the dynamics of the blood cell number, first of all, leucocytes and neutrophiles, and the 45-day survival. Supportive therapy for all the dogs, including the control ones, consisted in antibiotic treatment during the acute period of 7-24 days. It was shown that both pre-parations administered consecutively for about 17-21 days after irradiation positively influenced the dynamics of all blood cells but predominantly impacted the neutrophile number dynamics. The latter ones manifested a higher nadir level and an earlier onset of restoration in the G-SCF treated dogs in comparison with the control ones. The tendency to a positive influence on the survival has been shown in Neupomax-treated dogs exposed to 3.5 Gy of radiation (plus about 40%). The results of the experiments were in good accordance with the data by foreign authors who used Neupogen. This allows a conclusion that home-produced G-SCF preparations can replace their foreign analogues.
authors.forename: L M
authors.initials: LM
authors.lastname: Rozhdestvenskiĭ
authors.forename: T G
authors.initials: TG
authors.lastname: Shliakova
authors.forename: R A
authors.initials: RA
authors.lastname: Shchegoleva
authors.forename: N I
authors.initials: NI
authors.lastname: Lisina
authors.forename: V V
authors.initials: VV
authors.lastname: Zorin
mesh_terms: D000818:Animals; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D000069585:Filgrastim; D005720:Gamma Rays; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000627:therapeutic use; D007928:Lethal Dose 50; D007962:Leukocytes / Q000187:drug effects* / Q000528:radiation effects; D009504:Neutrophils / Q000187:drug effects / Q000528:radiation effects*; D011833:Radiation Injuries, Experimental / Q000097:blood* / Q000188:drug therapy; D011837:Radiation-Protective Agents / Q000008:administration & dosage*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D011837:Radiation-Protective Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim